Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT EPS (Diluted)

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
-$0.04-108%
Amgen logo
AmgenAMGN
$4.37+64.9%
Incyte logo
IncyteINCY
$2.81+37.7%
PVL
Palvella TherapeuticsPVLA
-$1.20-62.2%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$0.94-10.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$0.62+34.7%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M—
CapEx$158.0K+103%
Free cash flow$12.5M—

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other comprehensive income (loss)(142)105(612)(28)
Comprehensive income (loss)$14,867$(15,781)$3,102$(40,974)
Earnings (loss) per share:
Basic$0.11$(0.13)$0.03$(0.32)
Diluted$0.11$(0.13)$0.03$(0.32)
Weighted-average shares used in computing earnings (loss) per share:
Basic130,522126,997129,948126,519
Diluted135,898126,997135,951126,519

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s EPS (diluted)?
Arcutis Biotherapeutics, Inc. (ARQT) reported EPS (diluted) of $0.11 in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s EPS (diluted) changed year-over-year?
Arcutis Biotherapeutics, Inc.'s EPS (diluted) increased by 184.6% year-over-year, from -$0.13 to $0.11.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s EPS (diluted)?
Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s EPS (diluted) has grown at a -34.9% compound annual growth rate (CAGR), from -$4.17 to -$1.15.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Arcutis Biotherapeutics, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude